Valnoctamide

Summary

Valnoctamide (CHEMBL1075733) is a phase-3 clinical-stage small molecule (ATC N05CM13).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N05CM13
• Clinical trials: 1
• Chemistry: 143.23 Da · C8H17NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1075733
Name	Valnoctamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	20140
ATC	N05CM13
Molecular formula	C8H17NO
Molecular weight	143.23
InChIKey	QRCJOCOSPZMDJY-UHFFFAOYSA-N

SMILES: CCC(C)C(CC)C(=O)N

IUPAC name: 2-ethyl-3-methylpentanamide

Also known as: Axiquel, MCN-X-181, NSC-32363, NSC-34092, Valnoctamida, Valnoctamide, VALNOCTAMIDE, ValnoctamideÊ, valnoctamide, ValnoctamideÂ, ALPHA-ETHYL-BETA-METHYLVALERAMIDE

Patent coverage: 273 distinct patent families (1,112 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00140179	PHASE3	COMPLETED	Valnoctamide in Mania

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).